Back to Authors

Hallek, Michael

https://orcid.org/0000-0002-7425-4455

Mayo Clinic

University of Cologne

Citations 23

The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
Hallek, Michael , Österborg, Anders , Chanan‐Khan, Asher , Mahler, Michelle, Salman, Mariya, Wan, Ying , Sun, Steven , Zhuang, Sen Hong, Howes, Angela, Kay, Neil E.

Future Oncology | June 5, 2014 | Volume: 11 | Issue: 1 | Pages: 51-59

10.2217/fon.14.119 Get It

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, Natali , Bahlo, Jasmin, Eichhorst, Barbara , Bergmann, Manuela A., Elter, Thomas , Bauer, K. H. , Malchau, Gebhart, Rabe, Kari G. , Jäger, Ulrich, Eckart, Michael J., Busch, Raymonde, Fink, Anna‐Maria , Wendtner, Clemens‐Martin , Fischer, Kirsten , Hallek, Michael , Shanafelt, Tait D. , Stilgenbauer, Stephan , Döhner, Hartmut , Hopfinger, Georg , Kay, Neil E. , Chaffee, Kari G.

Blood | May 6, 2014 | Volume: 124 | Issue: 1 | Pages: 49-62

10.1182/blood-2014-02-556399 Get It

Key PointsPrognostic tool for CLL patients with high discriminatory power compared with conventional clinical staging systems. Prognostication on the individual patient level independent of clinical stage.